|

CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome

RECRUITINGPhase 4Sponsored by Shenyang Northern Hospital
Actively Recruiting
PhasePhase 4
SponsorShenyang Northern Hospital
Started2026-06-25
Est. completion2027-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The aim of this clinical trial is to investigate whether dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome. Coronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries. The main questions it aims to answer are * Does dapagliflozin lower coronary artery inflammation as measured by FAI? * Does dapagliflozin slow the progression of coronary plaques? Researchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months. Participants will: * Undergo percutaneous coronary intervention (PCI) for ACS * Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone. * Have a follow-up CCTA scan at 6 months after randomisation. * Receive follow-up phone calls at 3 and 6 months after randomisation

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria

1. Aged ≥ 18 years, irrespective of gender;
2. Meeting the diagnostic criteria for stage 4 CKM syndrome;
3. Able to cooperate with photon-counting CT examination during the index hospitalisation, with no contraindications to the examination;
4. Signed informed consent form.

Exclusion Criteria

1. Receiving SGLT2 inhibitor therapy within 4 weeks prior to enrolment;
2. Severe hepatic dysfunction (Child-Pugh class C);
3. History of recurrent urogenital tract infections;
4. History of allergy or intolerance to SGLT2 inhibitors;
5. Pregnant or lactating women;
6. Systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 60 mmHg;
7. Severe chronic kidney disease (eGFR \< 30 mL/min/1.73 m²);
8. Participation in other interventional clinical trials;
9. Other conditions deemed inappropriate for enrolment by the investigator(s).

Conditions3

ACS - Acute Coronary SyndromeHeart DiseaseSGLT2-Inhibitors

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.